Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF

MONDAY, Aug. 29, 2022 -- For patients with heart failure with mildly reduced or preserved ejection fraction, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the combined risk for worsening heart failure or cardiovascular...